Rearrangement of the Chromatin Organizer Special AT-rich Binding Protein 1 Gene, SATB1, Resulting from a t(3;5)(p24;q14) Chromosomal Translocation in Acute Myeloid Leukemia

SYNNE TORKILDSEN1,2,3, MARTA BRUNETTI1,2, LUDMILA GORUNOVA1,2, SIGNE SPETALEN4, KLAUS BEISKE4, SVERRE HEIM1,2,5 and IOANNIS PANAGOPOULOS1,2

1Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; 2Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Departments of 3Hematology and 4Pathology, Oslo University Hospital, Oslo, Norway; 5Faculty of Medicine, University of Oslo, Oslo, Norway

Abstract. Background/Aim: New chromosomal aberrations continue to be reported in acute myeloid leukemias (AML). The addition of more cases with the same genetic characteristics would establish an acquired aberration as a recurrent change, help determine its prognostic significance, and can provide insight into the mechanisms of leukemogenesis in patients with these rare abnormalities. Case Report: RNA-sequencing was performed on a patient with AML with the bone marrow karyotype 46,XY,t(3;5)(p24;q14)[5]/46,XY[10]. The translocation resulted in fusion of the SATB homeobox 1 gene (SATB1) (3p24) with an expression sequence tag with accession number BG503445 (5q14). The SATB1-BG503445 transcript may code for a SATB1 protein that would lack the C-terminal DNA-binding homeodomain. Conclusion: The present study is the first to demonstrate rearrangement and disruption of SATB1 in AML. Rearrangements of chromosome band 3p24 were reported in 24 additional AMLs but not in known leukemia-specific chromosomal abnormalities. Further studies are needed to determine whether SATB1-BG503445 or other aberrations of SATB1 are recurrent in AML.

Correspondence to: Ioannis Panagopoulos, Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, P.O.Box 4953 Nydalen, NO-0424 Oslo, Norway. Tel: +47 22782363, e-mail: ioannis.panagopoulos@rr-research.no

Key Words: Acute myeloid leukemia, chromosome translocation, RNA-sequencing, SATB1 gene, truncation.

Over the past two decades, acute myeloid leukemia (AML) has been transformed from a disease defined, classed, and staged based on cytological and other hematological characteristics alone to a disease classified largely based on genetic, genomic, and molecular characteristics (1, 2). Cytogenetic analysis of bone marrow cells has become an integral part of the clinical management of patients with hematological malignancies, not least AML, yielding diagnostic as well as prognostic information (http://www.uptodate.com/contents/cytogenetics-in-acute-myeloid-leukemia). Sometimes this type of information is decisive in choosing the optimal treatment for patients with AML as illustrated most pertinently by the finding at diagnosis of the chromosomal translocation t(15;17)(q22;q21), the hallmark of acute promyelocytic leukemia, an AML subtype treated and monitored differently from other subtypes (3). The detection of acquired chromosomal abnormalities in leukemia cells, in particular translocations and inversions, has helped identify genes located in the breakpoints that, when rearranged or otherwise deregulated, launch or contribute to the leukemogenic process (4). Numerous pathogenetic or genetic subgroups have thus been identified (4). Nevertheless, new recurrent or unique chromosomal aberrations (mainly balanced translocations) corresponding to smaller cytogenetic subgroups continue to be reported in AML and myelodysplastic syndromes (MDS) (5). The addition of more cases with the same genetic characteristics will establish the acquired aberration in question as a recurrent change, but may also help determine the prognostic significance of the aberration, as well as provide insights into the mechanisms of leukemogenesis in patients with these rare abnormalities (5).

We report here a t(3;5)(p24;q14) in a case of AML which resulted in the fusion of the SATB homeobox 1 gene...
investigated by standard methods. Chromosomal G-Banding analysis.

A 65-year-old man was diagnosed with MDS, classified as refractory cytopenia with multilineage dysplasia, in May 2013. No excess of blasts were described in the bone marrow smear at diagnosis, but a trisomy 8 chromosomal aberration was detected (see below). The patient received blood transfusions every other week until progression to AML occurred 15 months later. Examination of a bone marrow aspirate then showed normal hematopoiesis to be replaced by 50% blasts. Immunophenotypic analysis confirmed the myeloid origin of the blasts that were positive for cluster of differentiations (CD) CD34, CD117, and CD56. The CD34 count was only 7%, probably because the aspirate was heavily admixed with blood. Molecular genetic analysis was negative for fms related tyrosine kinase 3 (FLT3), nucleophosmin (NPM1), and CCAAT/enhancer binding protein alpha (CEBPA) mutations, and none of the most common AML-specific fusion transcripts were detected using the HemaVision 28Q RT-qPCR –KIT (DNA Diagnostic, Riskskov, Denmark).

The patient received induction therapy for AML with 90 mg/m² daunorubicin days 1-3 and 200 mg/m² cytarabine days 1-7. Although morphological remission was obtained, a persistent and significant aplasia remained even 4 months after induction treatment. It was therefore decided to stop further cytostatic treatment. Two months later, the patient was admitted to a local hospital due to dizziness, difficulties in finding words, memory loss, and headache. Magnetic resonance imaging showed a meningeval affection over most of the left hemisphere with mass effect, perceived as a manifestation of AML relapse, confirmed by examination of a new bone marrow aspirate. The patient was therefore treated with high-dose steroids and palliative radiotherapy (18 Gy), as well as hydroxyurea because of a stark increase in leukocyte and lactate dehydrogenase level. Despite this, the patient died 10 days after the beginning of radiation therapy.

**Case Report**

**G-Banding analysis.** Bone marrow cells were cytogenetically investigated by standard methods. Chromosomal preparations were made from metaphase cells of a 24-h culture, G-banded using Leishman stain, and karyotyped according to International System for Human Cytogenetic Nomenclature 2013 guidelines (6).

**Fluorescence in situ hybridization (FISH).** As part of our standard cytogenetic diagnosis, initial interphase FISH analyses of bone marrow cells were performed using the Cytocell multiprobe AML/MDS panel (Cytocell, Cambridge, UK) looking for 5/del(5q), 7/del(7q), del(20q), deletion of 17p13 (TP53), lysine methyltransferase 2A (KMT2A also known as MLL) rearrangements, promyelocytic leukemia-retinoic acid receptor alpha (PML–RARα) fusion created by t(15;17)(q22;q21), runt related transcription factor 1-RUNX1 translocation partner 1 (RUNX1–RUNX1T1) created by t(8;21)(q22;q22), and core binding factor beta- myosin heavy chain 11 (CBFB-MYH11) generated by the inversion inv(16)(p13q22). Fluorescent signals were captured and analyzed using the CytoVision system (Leica Biosystems, Newcastle-upon-Tyne, UK).

**RNA-seqencing.** Three micrograms of total RNA extracted from the patient’s bone marrow at the time of progression to AML were sent for high-throughput paired-end RNA sequencing at the Norwegian Sequencing Centre at Ullevål Hospital (http://www.sequencing.uio.no/). Detailed information about these analyses was given elsewhere (7). A total of 123 million reads were obtained. FASTQC software was used for quality control of the raw sequence data (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). TopHat-Fusion software was used for the discovery of fusion transcripts (8, 9).

**Reverse transcription polymerase chain reaction (RT-PCR) analyses.** For RT-PCR, 1 μg of total RNA was reverse-transcribed in a 20-μl reaction volume using iScript Advanced cDNA Synthesis Kit for RT-qPCR according to the manufacturer’s instructions (Bio-Rad Laboratories, Oslo, Norway). The 25 μl PCR volume contained 12.5 μl Premix Ex Taq™ DNA Polymerase Hot Start Version (Takara Bio Europe/SAS, Saint-Germain-en-Laye, France), 1 μl of cDNA, and 0.4 μM of each of the forward and reverse primers. The quality of the cDNA synthesis was assessed by amplification of a cDNA fragment of the ABL proto-oncogene 1, non-receptor tyrosine kinase (ABL1) gene using the primers ABL1-91F1 (5’-CAG CGG CCA GTA GCA TCT GAC TTT G-3’) and ABL1-404R1 (5’ CTC AGC AGA TAC TCA GCG GCA TTG C-3’) (7). Two primer combinations were used: The forward primer SATB1-3246F1 (5’-AGG AAA TGA AGC GTG CTA AAG TGT-3’) together with the reverse BG503445-359R1 (5’-CCT CTG AGA TGT AGT ACT CCA TGC-3’) and the forward SATB1-3147F1 (5’-CTC CCC AGG TGA AAA CAG CTA CTA-3’) with the
reverse BG503445-422R1 (5′-TCT TTC TTG CCA AAC TTG CCA TA-3′). The primers SATB1-3246F1 and SATB1-3147F1 correspond to positions 3246-3269 and 3147-3170 in the SATB1 reference sequence with accession number NM_002971.3. The reverse BG503445-359R1 and BG503445-422R1 primers correspond to positions 382-359 and 444-422 in the sequence with accession number BG503445.1. The PCRs were run on a C-1000 Thermal cycler (Bio-Rad Laboratories, Oslo, Norway) with an initial denaturation at 94°C for 30 s, followed by 35 cycles of 7 s at 98°C, 30 s at 55°C, 30 s at 72°C, and a final extension for 5 min at 68°C. Three microliters of the PCR products were stained with GelRed (Biotium, Hayward, CA, USA), visualized by electrophoresis through 1% agarose gel, and photographed. The remaining 22 μl PCR products were purified using the MinElute PCR purification kit (Qiagen Nordic, Oslo, Norway) and direct sequenced using the di-deoxy procedure with ABI Prism BigDye terminator v1.1 cycle sequencing kit (ThermoFisher Scientific, Oslo, Norway) on the Applied Biosystems Model 3500 Genetic Analyzer sequencing system (ThermoFisher Scientific, Oslo, Norway). BLAST software (http://blast.ncbi.nlm.nih.gov/) was used for computer analysis of sequence data.

Results

Karyotyping and FISH. G-Banding analysis of bone marrow cells at diagnosis (myelodysplastic syndrome–refractory cytopenia with multilineage dysplasia) yielded the karyotype 47,X,+8[2]/46,XY[15]. However, 15 months later when the disease had progressed to AML, the G-banding analysis of bone marrow cells yielded a different karyotype: 46,XY,t(3;5)(p24;q14)[5]/46,XY[10] (Figure 1A) with not one cell showing trisomy 8. FISH analysis showed no -5/del(5q), -7/del(7q), del(20q), deletion of TP53, MLL rearrangements, or PML-RARA, RUNX1-RUNXI71, or CBFB-MYH11 fusion. In particular, the RUNXI71 (8q22) probe showed only two green signals in all examined interphase nuclei confirming absence of trisomy 8 at this point in disease development.

Analysis of RNA-sequencing. Using the TopHat-Fusion on the raw sequencing data obtained by Norwegian Sequencing Centre, three fusions were found between chromosome bands 3p24 and 5q14 (Table I). Whereas two of them recombined non-genic and seemingly uninteresting sequences, the third was a fusion between SATB1 (from 3p24) and the sequence with accession number BG503445, which is an expressed sequence tag that has been spliced, mapped within the myocyte enhancer factor 2C (MEF2C) antisense RNA 1 locus (http://www.ncbi.nlm.nih.gov/gene/?term=MEF2C-AS1), and found to be expressed in embryonal carcinoma (https://www.ncbi.nlm.nih.gov/nucest/BG503445).

Molecular confirmation of the SATB1-BG503445 fusion. PCR with the primers ABL1-91F1 and ABL1-404R1 amplified cDNA fragments of ABL1, indicating that the synthesized cDNAs were of good quality (Figure 1B). PCR with the primer sets SATB1-3246F1/BG503445-359R1 and SATB1-3147F1/BG503445-422R1 amplified a 120 bp and a 280 bp cDNA fragment, respectively (Figure 1B). Direct sequencing of the amplified fragments verified the presence of the SATB1-BG503445 transcript, with the fusion point identical to that found with TopHat (Figure 1C).

Discussion

We present a case of AML in which the leukemia cells had a novel t(3;5)(p24;q14) chromosomal translocation as the sole cytogenetic abnormality. The molecular analysis of the translocation showed that it resulted in fusion of the SATB1 gene with the expressed sequence tag BG503445. The SATB1 gene is expressed predominantly in the thymus and encodes a matrix protein which binds nuclear matrix and scaffold-associating DNAs through a unique nuclear architecture (10). It is required for development of thymocytes and activation of helper T cells 2 (Th2) cells. Without the SATB1 protein, thymocyte development is blocked at the CD4+CD8+ stage and Th2 cells cannot become activated and produce cytokines (10). The SATB1 protein was

Table I. Fusions between chromosomal bands 3p24 and 5q14 which were found with the TopHat-Fusion program. The sequences corresponding to the SATB1-BG503445 fusion transcript are in bold.

<table>
<thead>
<tr>
<th>3p24-Fusion point</th>
<th>5q14-Fusion point</th>
<th>Fifty bases on the left side of the fusion (3p24)</th>
<th>Fifty bases on the right side of the fusion (5q14)</th>
</tr>
</thead>
<tbody>
<tr>
<td>18419661</td>
<td>88600566</td>
<td>CTAAAGTGTCTCAAGACACTGTGGTCA</td>
<td>GAATTCTACTAGTCATGGAGAGA</td>
</tr>
<tr>
<td>22423821</td>
<td>77940164</td>
<td>ACGAAAAAGATTTGCCGATATCCGAG</td>
<td>AAACATGGTCTGCCATGGTACAT</td>
</tr>
<tr>
<td>22423828</td>
<td>77940156</td>
<td>GATATTTCTGCTGATATCCGAGAAAGCA</td>
<td>GAGTTGTCAGCGGCGAAAAGACAGA</td>
</tr>
</tbody>
</table>

Molecular confirmation of the SATB1-BG503445 fusion.
Figure 1. Cytogenetic and molecular genetic analysis of bone marrow cells from the patient. A: Partial karyotype showing the der(3)t(3;5)(p24;q14) and der(5)t(3;5)(p24;q14) together with the corresponding normal chromosome homologs. Breakpoint positions are indicated by arrows. B: Gel electrophoresis showing the amplified cDNA fragments. Lane 1, amplification of an ABL proto-oncogene 1, non-receptor tyrosine kinase (ABL1) cDNA fragment using the primers ABL1-91F1 and ABL1-404R1. Lanes 2 and 3, amplifications of cDNA fragments using the primer combinations SATB1-3246F1/BG503445-359R1 and SATB1-3147F1/BG503445-422R1, respectively. M, 1 kb DNA ladder (GeneRuler, ThermoFisher). C: Partial sequence chromatogram of the amplified cDNA fragment showing the junction point of the SATB homeobox 1 (SATB1) gene with the sequence with accession number BG503445. D: Illustration of the SATB1 protein and its functional domains. Arrow shows the breakpoint. PDZ: PSD95/Dlg/ZO-1 (PDZ)-like dimerization domain; CUT: CUT DNA binding motif.
also shown to play an important role in hematopoietic stem cells self-renewal, in lymphoid lineage specification, in epidermal differentiation, and brain function (10-12).

SATB1 folds chromatin into loops and recruits chromatin remodeling and modifying enzymes to these DNA loops. Depending on the genomic location, SATB1 attracts histone deacetylases and other histone modifying enzymes to the site and a change in histone marks occurs that may either activate or repress transcription (11). SATB1 controls a plethora of genes many of which [erb-b2 receptor tyrosine kinase 2 (ERRB2), ABL1, matrix metallopeptidase 2 (MMP2), E-cadherin (CDH1), vascular endothelial growth factor B (VEGFB), transforming growth factor beta 1 (TGFBI), and others] are involved in carcinogenesis (10-12). Thus, expression of SATB1 is associated with many types of cancer, including colorectal, breast, pancreatic, nasopharyngeal, bladder, prostate, lung, ovarian, liver, glioma, lymphoma, and kidney tumors (11). In most cancer types, SATB1 expression is associated with progression and poor prognosis (11) and references therein.

SATB1 has been linked to AML ([10] and references therein). Disruption of the distal enhancer of the Spi-1 proto-oncogene, SPI1, gene (also known as PU.1), coding for an E26 transformation-specific (ETS)-domain transcription factor, reduces its expression leading to AML in mice. A single nucleotide polymorphism which is frequently associated with human AML, was identified within the distal enhancer of the SPI1 gene and specifically inhibits SATB1 binding, causing reduced SPI1 expression in myeloid progenitor cells ([10] and references therein).

The present study is the first to demonstrate rearrangement and disruption of SATB1 in hematological malignancies stemming from the chromosomal translocation t(3;5)(p24;q14).

Molecular analysis of the translocation showed fusion of the SATB1 gene with a sequence with accession number BG503445 from 5q14 resulting in a putative SATB1 truncated protein (Figure 1). This protein would contain the nuclear localization signal domain, the N-terminal domain of SATB1 which is involved in various interactions with chromatin proteins, the PSD95/Dlg/ZO-1 (PDZ)-like dimerization domain, the nuclear matrix targeting sequence, and the first CUT DNA binding motif (Figure 1D). It would lack the C-terminal homeodomain DNA binding domain which binds to DNA as a monomer or homo- or heterodimer playing a part in the transcriptional regulation of key eucharyotic developmental processes (13). The precise role of SATB1 truncated protein in the development of leukemia cannot be predicted without functional studies. However, anomaly in transcription regulation can be assumed. Alternatively, loss of a functional SATB1 allele might be the important factor in leukemogenesis.

Chromosomal aberrations resulting in gene truncation have been repeatedly described for the RUNXI and ETS variant 6 (ETV6) genes (14, 15). The translocation generates a premature stop codon in the open reading frames leading to expression of C-terminal truncated forms of the RUNX1 or ETV6 proteins (14, 15). Truncated RUNX1 proteins interfere with normal RUNX1 protein (16-18). Truncated forms of ETV6 were shown to have a dominant-negative effect on normal ETV6 function and disrupt both primitive and definitive hematopoiesis in the zebrafish model (19).

In the Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer (http://cgap.nci.nih.gov/Chromosomes/Mitelman; at May 4, 2016), 24 cases of AML can be found with breakpoints in chromosome band 3p24 where SATB1 maps. SATB1 may or may not be pathogenetically involved in these leukemias. The same goes for other cases with breakpoints mapped near 3p24, for example, for two myeloid leukemias with t(3;5)(p21;q13-14) (20, 21); the seeming cytogenetic variability is not so large that it might not be due to interpretation difficulties. Greater awareness of the role of SATB1 in leukemic contexts certainly seems warranted.

Competing Interests
The Authors declare that they have no competing interests.

Acknowledgements
This work was supported by grants from the Norwegian Radium Hospital Foundation.

References


